Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Antimicrobial Resistance Surveillance Market is projected to expand from USD 6.54 billion in 2025 to USD 9.27 billion by 2031, reflecting a compound annual growth rate of 5.98%. This sector comprises specialized diagnostic instruments and software platforms designed to systematically track and analyze how pathogens respond to antimicrobial drugs. The primary forces propelling this growth include the critical need to address the rising prevalence of multidrug-resistant organisms and the global enforcement of strict antimicrobial stewardship programs. Additionally, significant government efforts and funding aimed at bolstering laboratory infrastructure and ensuring data compatibility are actively speeding up the adoption of these essential monitoring systems within healthcare networks.

Despite this progress, major hurdles exist due to the high costs associated with installing and maintaining advanced surveillance technologies, which hinders adoption in resource-limited settings. This financial constraint frequently restricts the spread of automated reporting capabilities in developing regions that lack adequate technical infrastructure. According to the World Health Organization, 127 countries had formally joined the Global Antimicrobial Resistance and Use Surveillance System by 2025 to support standardized monitoring initiatives, yet the cost barrier continues to challenge universal implementation.

Market Drivers

The escalating prevalence of multi-drug resistant infections acts as the main catalyst for the Global Antimicrobial Resistance Surveillance Market, creating an urgent need to expand diagnostic capabilities. As pathogens evolve to resist standard treatments more rapidly, healthcare systems are forced to implement advanced monitoring frameworks capable of detecting resistance patterns in real time. This rise in biological threats fuels the demand for high-throughput systems that support empirical therapy and containment strategies. According to The Lancet’s September 2024 systematic analysis, bacterial antimicrobial resistance is forecast to cause over 39 million direct deaths globally between 2025 and 2050, compelling diagnostic developers to prioritize technologies that identify emerging resistance markers to reduce this anticipated mortality burden.

A second critical driver is the increase in public and private funding for AMR research and infrastructure, which directly addresses the high costs of building comprehensive surveillance networks. Governments and international organizations are actively financing the modernization of laboratories to bridge data gaps across human, animal, and environmental health sectors. For instance, the UK Government announced in May 2024 a financial package of £85 million to bolster international efforts, including surveillance strengthening in the Caribbean and Africa. Despite such investments, gaps remain; the Global Coalition on Aging reported in February 2024 that only four out of eleven analyzed high-income countries regularly monitored water for antimicrobial resistance genes, indicating a sustained market opportunity for environmental surveillance solutions.

Market Challenges

The significant financial investment needed to install and maintain diagnostic technologies acts as a major restraint on the antimicrobial resistance surveillance market's growth. This cost barrier severely restricts the uptake of automated reporting systems, especially in regions with limited healthcare budgets where funding digital infrastructure is difficult. As a result, many healthcare facilities in developing economies persist in using manual data collection methods instead of integrating digital tracking platforms, which effectively limits the potential market size for diagnostic manufacturers.

Furthermore, the inability to secure necessary budget allocations directly impedes the scalability of global surveillance networks. When medical institutions are unable to afford initial capital expenditures or ongoing operational costs, vendors experience reduced demand in high-burden regions. According to the World Health Organization, only 11 percent of countries had allocated dedicated financial resources to implement their national antimicrobial resistance action plans in 2024. This lack of specific financing leaves a large portion of the potential global market untapped, thereby stalling the widespread deployment of standardized monitoring instruments.

Market Trends

The widespread adoption of Whole Genome Sequencing (WGS) is significantly transforming the Global Antimicrobial Resistance Surveillance Market by allowing for precise genetic characterization of pathogens beyond traditional phenotypic methods. This technological advancement enables public health networks to quickly identify transmission clusters, track the evolution of multi-drug resistant clones, and accurately distinguish between relapse and reinfection. As laboratories increasingly rely on genomic data to guide containment strategies, molecular diagnostics are becoming a standard element of national monitoring infrastructures. According to the European Centre for Disease Prevention and Control’s November 2025 report, 84 percent of participating laboratories across 26 countries reported using molecular methods, including PCR and whole-genome sequencing, to select isolates for advanced antimicrobial susceptibility testing.

Concurrently, the integration of Artificial Intelligence and Machine Learning is revolutionizing how surveillance data is processed and used for predictive analytics. These advanced computational tools analyze vast and complex datasets from various sources, facilitating the early detection of emerging resistance hotspots and the optimization of empirical prescribing practices. By automating the identification of resistance patterns, AI-driven platforms drastically reduce the time needed to generate actionable insights, attracting significant investment into smart surveillance ecosystems. For example, Alliance News reported in November 2025 that a strategic partnership between GSK and the Fleming Initiative committed £45 million to fund approximately 50 scientific roles focused on using advanced AI and supercomputing to track and mitigate drug-resistant infections.

Key Players Profiled in the Antimicrobial Resistance Surveillance Market

• Luminex Corporation (DiaSorin)
• Thermo Fisher Scientific Inc.
• Accelerate Diagnostics, Inc.
• Liofilchem S.r.I.
• Becton, Dickinson, and Company
• Biomerieux Inc.
• Bruker Corp.
• Danaher Corporation
• Merck KgaA
• Abbott Laboratories Inc.

Report Scope

In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories:

Antimicrobial Resistance Surveillance Market, by Solution:

• Diagnostic kits
• Diagnostic systems
• Surveillance software
• Services

Antimicrobial Resistance Surveillance Market, by Application:

• Clinical Diagnostics
• Public Health Surveillance
• Other Applications

Antimicrobial Resistance Surveillance Market, by End User:

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Antimicrobial Resistance Surveillance Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimicrobial Resistance Surveillance Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.